Evidence Grade C — Moderate human evidence. 346 published studies, 88 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide discovered in 1977 from rabbit brain during sleep experiments. Despite its name, its connection to sleep remains unproven — after nearly five decades of research, no specific receptor has been identified and multiple independent laboratories have failed to consistently replicate the original sleep-promoting claims.
DSIP is also known by these brand and alternate names:
346 published studies: 88 human, 236 animal, 26 in-vitro, 10 reviews
DSIP has no marketing authorisation. Small clinical studies from the 1980s investigated sleep and withdrawal symptom applications, but these trials had significant methodological limitations including small sample sizes and inadequate controls. No modern clinical trials meeting current standards have been conducted.
The compound's discovery preceded the identification of its mechanism — and after nearly five decades, no specific receptor has been definitively established. This mechanistic uncertainty distinguishes DSIP from most other research compounds. Products available through unregulated channels lack pharmaceutical quality assurance.
Research has not identified a specific receptor or defined mechanism for DSIP. Proposed mechanisms include interactions with multiple neurotransmitter systems including NMDA receptors, opioid systems, and GABAergic signalling. The inability to identify a clear receptor target or consistent mechanism is a fundamental limitation of this compound's evidence base.
Research suggests the inability to identify a receptor, a gene, or a reproducible sleep-inducing mechanism after 40+ years is a fundamental scientific concern. All clinical studies are from the 1980s with small sample sizes and outdated methodology. No modern randomised controlled trials exist. A paradox also remains unexplained: DSIP levels in the body actually decrease during the sleep states it was originally claimed to promote. The compound's biological activity, if any, may be unrelated to sleep. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for DSIP sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino acid nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its molecular weight is 848.81 Da (CAS 62568-57-4). Discovered in 1974/1977 by Schoenenberger and Monnier from rabbit cerebral venous blood during electrically induced sleep, DSIP remains one of the most controversial compounds in peptide research. Despite over 40 years of investigation, no specific receptor has been identified and no gene encoding DSIP has been found in any sequenced genome. The circulating half-life is estimated at 2-15 minutes. Paradoxically, plasma DSIP levels decrease rather than increase during REM and slow-wave sleep.
Research suggests DSIP may modulate multiple neurotransmitter systems rather than acting through a single receptor. Proposed mechanisms include interaction with NMDA receptors, opioid system modulation (effects are partially naloxone-reversible), MAPK cascade activation, and modulation of GABAergic transmission. DSIP has been reported to alter the ratio of ACTH to beta-endorphin release, potentially influencing stress responses. The compound may act as a sleep-promoting factor by modulating circadian rhythms rather than directly inducing sleep. However, the fundamental mechanism remains unresolved, as no specific DSIP receptor or binding protein has been conclusively identified.
A small insomnia study (N=14) reported improved sleep efficiency with DSIP administration. A larger withdrawal study (N=107) reported 97% improvement in opiate withdrawal symptoms and 87% improvement in alcohol withdrawal symptoms, though 13-22% of subjects were lost to follow-up. All clinical trials date from the 1980s with sample sizes typically under 20. Multiple independent laboratories attempted to replicate the sleep-inducing effects: Obal (1985), Kovalzon (1986, 1994, 1999), and Borbely/Tobler (1989) all failed to replicate the original sleep-promoting findings, creating a fundamental reproducibility crisis.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 27 vendor listings
View pricing data across vendors and countries for DSIP
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
